FindTrial
Sign In

The Geneva Covid-19 CVD Study

Retrospective Observational Study to Compare the Short, Mid- and Long-term Prognosis and Outcomes of SRAS-CoV-2 Infected Hospitalized Patients With Cardiovascular Disease (CVD) to SARS-CoV-2 Infected Hospitalized Patients Without CVD: The Geneva Covid-19 CVD Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04384029
Enrollment
1927
Registered
2020-05-12
Start date
2020-03-24
Completion date
2021-07-31
Last updated
2021-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, CVD

Brief summary

In this study, the investigators propose to analyse the clinical data of all patients admitted in Geneva University Hospitals (HUG) or in a care center in Geneva who are diagnosed with COVID-19. CVD being one of the most important risk factors for developing a severe form of the disease, the investigators will explore the prognosis and clinical outcomes of those patients according to their CVD history as well as newly onset CVD during hospitalization. Moreover, as further evidence is needed on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors for SARS-CoV-2 infected patients, the investigators will study prognosis and outcomes according to the patients' medications. Finally, the investigators propose to evaluate hospital length of stay and cost. The aim, therefore, is to collect information and scientific evidence from patients hospitalized and diagnosed positive for COVID-19, in order to evaluate if previous (or newly onset) CVD may influence outcomes and costs.

Detailed description

Hypothesis: COVID-19+ hospitalized patients with preexisting CVD or newly onset CVD at time of hospitalization have different clinical outcomes compared to those without CVD and COVID-19+. Objectives: The primary aim of this study is to gather observational data, starting from February 1st 2020 until the end of the pandemic, to compare clinical outcomes COVID+ hospitalized patients at HUG or in a care center in Geneva with pre-existing or newly onset CVD, to COVID+ hospitalized patients at HUG or in a care center in Geneva without pre-existing CVD. The secondary aims of this study are: * To determine the association between COVID-19 disease and CVD, based on: age, previous CV diseases, CV risks factors, CV medications (e.g. ACE Inhibitors or angiotensin II receptor antagonists) * To explore CVD profiles that may influence COVID-19 disease outcomes * To determine the cause of death in CVD patients (either with preexisting CVD or newly diagnosed with CVD) * To understand the vulnerability of the myocardium (new event of either heart failure, acute coronary syndrome, arrhythmia, myocarditis) in patients with COVID-19 disease.

Interventions

OTHERCovid-19 + patients

all the patients hospitalized in Geneva and SARS-Cov2 positive

Sponsors

François MACH
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject is ≥18 years of age. * Patient diagnosed SARS-CoV-2 positive at time of hospitalization. * In case of the subject accepting the follow-up at 30 days and 1 year, Signed Patient Informed Consent (PIC) form

Exclusion criteria

* Patients unwilling to provide informed consent for the follow-up.

Design outcomes

Primary

MeasureTime frameDescription
mortality 1 year after hospitalization1 year after hospitalizationTo compare mortality 1 year after hospital stay in COVID-19+ patients with or without preexisting CVD.
mobidity discharge0 days after hospitalizationTo compare morbidity during hospital stay in COVID-19+ patients with or without preexisting CVD.
mobidity at 30 days30 days after hospitalizationTo compare morbidity 30 days after hospitalization in COVID-19+ patients with or without preexisting CVD.
mobidity 1 year after hospitalization1 year after hospitalizationTo compare morbidity 1 year after hospitalization stay in COVID-19+ patients with or without preexisting CVD.
mortality discharge0 days after hospitalizationTo compare mortality during hospital stay in COVID-19+ patients with or without preexisting CVD.
mortality 30 days after hospitalization30 days after hospitalizationTo comparemortality30 days after hospital stay in COVID-19+ patients with or without preexisting CVD.

Secondary

MeasureTime frameDescription
Clinical outcomes according to medication at admission0 days after hospitalizationClinical outcomes according to medication at admission evaluated at hospital discharge
Clinical outcomes related to preexisting cardiovascular risk factors at admission0 days after hospitalizationClinical outcomes related to preexisting cardiovascular risk factors at admission evaluated after hospital discharge
New onset of CVD induced by COVID-19 disease0 days after hospitalizationNew onset of CVD induced by COVID-19 disease at discharge
Cost of hospital stay0 days after hospitalizationCost of hospital stay
Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).30 days after hospitalizationClinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).
Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).1 year after hospitalizationClinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026